F-Star Therapeutics - der Star am Pharma Himmel
Seite 1 von 1 Neuester Beitrag: 07.03.23 15:53 | ||||
Eröffnet am: | 16.12.20 21:38 | von: BusinessPlay. | Anzahl Beiträge: | 14 |
Neuester Beitrag: | 07.03.23 15:53 | von: Vassago | Leser gesamt: | 5.636 |
Forum: | Börse | Leser heute: | 5 | |
Bewertet mit: | ||||
F-star is a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of F-star’s innovative tetravalent mAb2 bispecific antibodies.
With four distinct binding sites in a natural human antibody format, F-star believes its proprietary technology will overcome many of the challenges facing current immuno-oncology therapies, because of the strong pharmacology enabled by tetravalent bispecific binding.
F-star’s vision is to transform the treatment of cancer through the development of clinically differentiated and well tolerated mAb2 bispecific antibodies, which are designed to address multiple immune evasion pathways that limit the effect of current immuno-oncology therapies.
F-star’s leadership team has decades of combined experience in pharma and biotech. Together they have successfully brought 20 drugs to market.
https://investors.f-star.com/
Zahlen für Q3/21
- Umsatz 1 Mio. $
- Verlust 11 Mio. $
- Cash 71 Mio. $
- MK 118 Mio. $
https://investors.f-star.com/news-releases/...-2021-financial-results
Sehr interessantes Biotech.
Merck KGaA übt eine weitere Lizenz-Option aus
"Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will be responsible for all future development and commercialization costs and will pay future success-based milestones and royalties on any net sales, resulting from programs covered by the agreement."
https://investors.f-star.com/news-releases/...-kgaa-darmstadt-germany
Mk 76 Mio. $, ich gebe prinzipiell wenig auf Analystenkursziele und Einschätzungen, aber falls jemand Wert darauf legt:
- 7 Coverings --> 7x kaufen
- das niedrigste Kursziel liegt bei 15$
https://www.wsj.com/market-data/quotes/FSTX/research-ratings
Zahlen für 2021
- Umsatz 21 Mio. $
- Verlust 31 Mio. $
- Cash 79 Mio. $
- MK 62 Mio. $
Multiple Clinical Program Updates Expected in 2022
https://investors.f-star.com/news-releases/...1-financial-results-and
Zahlen für Q1/22
- Umsatz 2,6 Mio. $
- Verlust 12 Mio. $
- Cash 69 Mio. $
- MK 54 Mio. $
- Four Clinical Readouts Anticipated Throughout 2022
https://investors.f-star.com/news-releases/...-2022-financial-results
Übernahme
- invoX (Tochter von Sino Biopharmaceutical) will FSTX in einem All-Cash-Deal übernehmen
- Bewertung 161 Mio. $ bzw. 7,12$ Cash je Aktie
https://investors.f-star.com/news-releases/...ics-inc-pioneering-next
https://investors.f-star.com/node/9301/html
https://endpts.com/f-star-invox-pharma-sale-cfius-national-security/
Das Übernahmeangebot wurde nochmal bis zum 8. Februar verlängert.
https://www.sec.gov/ix?doc=/Archives/edgar/data/...893/d426058d8k.htm
- Kündigt CFIUS-Freigabe für die geplante Übernahme durch invoX Pharma an
https://investors.f-star.com/news-releases/...fius-clearance-proposed